Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2023 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
March 23, 2023 16:01 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial...
March 15, 2023 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
March 11, 2023 13:21 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure

ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of...
February 28, 2023 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

ENCINITAS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
January 26, 2023 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day

Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase...
January 12, 2023 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

ENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
January 05, 2023 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Host R&D Event on January 26, 2023

ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
December 01, 2022 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

The Phase 2 trial in psoriasis will explore a broad range of doses based on Phase 1 data demonstrating class-leading safety and TYK2 target coverage Phase 2 trials of VTX958 for psoriatic arthritis...
November 22, 2022 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

ENCINITAS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...